Douglas Giordano
Chief Executive Officer at ANACOR PHARMACEUTICALS INC
Net worth: 138 730 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Roxanne Lagano | F | 59 | 12 years | |
| N. Coles | M | 63 |
Cerevel Therapeutics LLC
 Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | 6 years |
| Gabrielle Greene-Sulzberger | F | 63 |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 5 years |
| Margaret M. Madden | F | - | 8 years | |
| Albert Bourla | M | 62 | 31 years | |
| Frank D'Amelio | M | 66 | 17 years | |
| Adam Koppel | M | 54 |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 years |
| Deborah Baron | F | 55 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 3 years |
| Suneet Varma | M | 55 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 23 years |
| Christopher Gordon | M | 51 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018.
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | 6 years |
| Bryan Supran | M | - | 8 years | |
| Marijn Dekkers | M | 65 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018.
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | 6 years |
| Norbert Riedel | M | 66 |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 6 years |
| Adam Stone | M | 44 |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 18 years |
| Sue Desmond-Hellmann | M | 66 | 4 years | |
| Ronald Renaud | M | 55 | 1 years | |
| Michael McCallister | M | 71 | 11 years | |
| Joseph Edelman | M | 67 |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 25 years |
| Brian Bonnell | M | 50 | 6 years | |
| Deval Patrick | M | 67 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 4 years |
| Ruth McKernan | M | 66 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 4 years |
| Douglas Lankler | M | 58 | 25 years | |
| Morris J. Birnbaum | M | 72 |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | 5 years |
| Ellen Hukkelhoven | M | 37 |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 11 years |
| Rady Johnson | M | 63 | 30 years | |
| Kunal Kandimalla | M | - |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 6 years |
| Susan Altschuller | M | 42 |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | 1 years |
| Deborah Waterhouse | F | 57 |
ViiV Healthcare Ltd.
 ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | 7 years |
| Orly Mishan | F | - |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 5 years |
| Kathleen Tregoning | F | 53 | 4 years | |
| Fany de la Cruz | M | - |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | - |
| Dan Littman | M | 71 | 6 years | |
| Nina Kjellson | F | 49 | 3 years | |
| Sarah Marriott | F | 46 | 3 years | |
| Mark Bodenrader | M | 51 | 5 years | |
| Agnieszka Gallagher | F | 51 |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | 7 years |
| Scott Akamine | M | 40 | 3 years | |
| Greg Parekh | M | - |
New Rhein Healthcare Investors
 New Rhein Healthcare Investors Investment ManagersFinance New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania. | 14 years |
| Praveen Tipirneni | M | 55 | 3 years | |
| Joseph Echevarria | M | 66 | 9 years | |
| Douglas Williams | M | 66 | 3 years | |
| Sally Susman | F | 62 | 17 years | |
| David Hoffmeister | M | 69 | 6 years | |
| Ivan Philip Gergel | M | 64 |
New Rhein Healthcare Investors
New Rhein Healthcare Investors Investment ManagersFinance New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania. | 6 years |
| Robert Scully | M | 74 | 11 years | |
| Ronald Blaylock | M | 64 | 7 years | |
| Shantanu Narayen | M | 60 | 11 years | |
| Susan Hockfield | M | 73 | 4 years | |
| Sanjay Khosla | M | 71 | 11 years | |
| Suzanne Johnson | F | 66 | 17 years | |
| Oleg Nodelman | M | 47 | 3 years | |
| Gregory Norden | M | 66 | 11 years | |
| Scott Gottlieb | M | 51 | 5 years | |
| Hossein Ekrami | M | - |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 17 years |
| Jim Smith | M | 64 | 10 years | |
| Helen Hobbs | M | 71 | 13 years | |
| Don Abbey | M | 57 | 6 years | |
| James Quincey | M | 59 | 4 years | |
| Patrick Morrow | M | - |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 7 years |
| Susan Grant | F | - |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | - |
| Markus Goebel | M | - |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | - |
| Nathan Sadeghi-Nejad | M | - |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | 2 years |
| Raymond Sanchez | M | 63 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Steere | M | 87 | 37 years | |
| Henry McKinnell | M | 81 | 8 years | |
| Ian Read | M | 71 | 41 years | |
| Jeffrey Kindler | M | 68 | 8 years | |
| Paul Berns | M | 57 | 4 years | |
| Kyle A. Lefkoff | M | 64 | 21 years | |
| Amy Schulman | F | 63 | 6 years | |
| George Cole | M | 75 |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 3 years |
| Glenn David | M | 52 | 24 years | |
| Martin MacKay | M | 68 |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 14 years |
| Richard Cunningham | M | 54 |
Icagen, Inc.
 Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | 6 years |
| Gary G. Altman | M | 77 |
Icagen, Inc.
Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | 1 years |
| Dennis Ausiello | M | 78 | 13 years | |
| Steven C. Riggs | M | 65 | 26 years | |
| Bruce Given | M | 69 |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | 9 years |
| David Shedlarz | M | 75 | 31 years | |
| Lucy Shapiro | M | 83 | 16 years | |
| Heidi Chen | F | 57 | 12 years | |
| Wendell Wierenga | M | 76 | 13 years | |
| Mark Leschly | M | 55 | 14 years | |
| George A. Lorch | M | 82 | 15 years | |
| Constance J. Horner | F | 82 | - | |
| Charles H. Hill | M | 69 | 31 years | |
| Charles Baum | M | 65 | 15 years | |
| Andrea N. Flynn | M | - | 1 years | |
| Jonathan Emms | M | - | 20 years | |
| Alexandra Kropotova | M | 51 | 5 years | |
| Ranjeev Krishana | M | 50 | 7 years | |
| Richard H. Sherman | M | 78 | 27 years | |
| Nicholas A. Saccomano | M | 65 | 30 years | |
| Ron Squarer | M | 57 | 7 years | |
| John Orwin | M | 59 | 7 years | |
| Shalini Sharp | F | 49 | 2 years | |
| Olivier Brandicourt | M | 68 | 13 years | |
| Dana George Mead | M | 88 | 12 years | |
| Gil van Lunsen | M | 81 | 17 years | |
| Lori McNeill | F | 51 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| United Kingdom | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Douglas Giordano
- Personal Network